Abuse of Telazol has been documented.<ref>{{cite journal|last=Quail|first=MT|author2=Weimersheimer, P |author3=Woolf, AD |author4=Magnani, B |title=Abuse of telazol: an animal tranquilizer.|journal=Journal of Toxicology: Clinical Toxicology|year=2001|volume=39|issue=4|pages=399–402|pmid=11527235|doi=10.1081/clt-100105161}}</ref> Animal studies have also shown that tiletamine produces rewarding and reinforcing effects.<ref>{{cite journal |vauthors=de la Peña JB, Lee HC, de la Peña IC, Woo TS, Yoon SY, Lee HL, Han JS, Lee JI, Cho YJ, Shin CY, Cheong JH |title=Rewarding and reinforcing effects of the NMDA receptor antagonist-benzodiazepine combination, Zoletil®: difference between acute and repeated exposure |journal=Behavioural Brain Research |volume=233 |issue=2 |pages=434–42 |year=2012 |pmid=22659394 |doi=10.1016/j.bbr.2012.05.038 }}</ref> Tiletamine products are classified as [[Controlled Substances Act#Schedule III controlled substances|Schedule III]] [[controlled substance]]s in the United States.<ref>{{cite web|title=Lists of: Scheduling Actions, Controlled Substances, Regulated Chemicals|url=http://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf|publisher=Drug Enforcement Administration|accessdate=5 January 2012}}</ref>
